DAA regimen were: genotype 1 of HCV, detectable viral load, cirrhosis diagnosed

From our patients only 92 (76.66 ) had F4 fibrosis in accordance with the FibroMax. In 4 instances the earlier fibrosis investigated by FibroMax or Fibroscan was F3 plus the individuals had severe comorbidities. Despite these data, the evaluation of FibroMax during the National Program showed F2 fibrosis and have been ineligible for DAA therapy. In one particular case, the outcome of FibroMax was F2 however the patient had significant clinical indicators of cirrhosis and the therapy was approved. For twentytwo patients the FibroMax showed F3 fibrosis (19.16 ). However, they had been known with compensated cirrhosis previously diagnosed by: FibroMax, Fibroscan, liver biopsy or by clinical findings like esophageal varices. Amongst them, 15 individuals were considered eligible for therapy (65.21 ): 11 individuals have already received the approval (78.57 ) and 4 individuals are awaiting the commission's choice. Eight patients with out clinical indicators of cirrhosis have been declared title= s11606-015-3271-0 ineligible (34.78 ), despite the earlier evaluation of fibrosis by non-invasive Outcome of catheter tip culture showed Proteus mirabilis and bronchial aspirate solutions.A31. The safety of direct acting antivirals in HCV compensated cirrhotic sufferers - an interim analysis Victoria Aram1,two, Remulus Catan1,two, Cristina Dragomirescu2, Cristina Murariu2, Anca Leutean2, Laureniu Stratan2, Alexandra Badea2, Alina Orfanu1,2, Anca Negru1,2, Raluca Nstase2, Violeta Molagic2, Daniela Munteanu1,2, Ctlin Tilican1,2, Mihaela Rdulescu1,2, Ioan Diaconu2, Violeta Ni2, Iulia Bodoca2, Cristina Popescu1,2 1 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; two National Institute for Infectious Diseases "Prof. Dr. Matei Bal", Bucharest, Romania Correspondence: Remulus Catan (catana.remulus@yahoo.com) BMC Infectious Ailments 2016, 16(Suppl four):A31. Background The regimen containing NS5A inhibitor - ombitasvir, protease inhibitor paritaprevir boosted with ritonavir and non-nucleoside inhibitor dasabuvir (OPrD) linked with ribavirin was authorized in Romania from November 2015 for genotype 1 HCV infected patients with compensated cirrhosis. The safety information with regards to this therapeutic regimen came from clinical research where many individuals with extreme comorbidities were excluded. The information coming from real-life are more relevant within this context. Objective: the aim of our study will be to analyze and to report the unwanted side effects that occurred in the course of and soon after OPrD-riba regimen and also the management of those unwanted side effects.DAA regimen were: genotype 1 of HCV, detectable viral load, cirrhosis diagnosed by FibroMax (BioPredictive France) if fibrotest is much more than 0.75 and compensated cirrhosis based on Child Pugh score (Kid Pugh score A ?five and six points). Objectives: to analyze all of the causes that led to the failure of access to DAA regimen via Romanian National Plan. Methods We performed a prospective study in which we enrolled all of the individuals known with compensated cirrhosis who received vouchers for access to the therapy (FibroMax, viral load and HCV genotyping test). The current status of every single patient was analyzed. Outcomes 120 sufferers have been included inside the DAA therapy program in title= jir.2014.0021 Third Division of Matei Bal Institute. Among them: 88 (78.33 ) received the approval, 17 individuals are awaiting the approval (14.16 ), 3 patients were ineligible regardless of F4 fibrosis as a result of the diagnosis of hepatocellular carcinoma and 12 (ten ) had fibrosis less than F4 and have been ineligible in line with the neighborhood guideline.